Corcept Therapeutics (CORT) Stock: Buy, Sell, or Hold?
$73.35
-1.68 (-2.23%)
▼
5d:
-10.47%
30d:
-39.48%
90d:
-34.61%
QUANTITATIVE VERDICT
HOLD
LOW Confidence (91%)
Quality Score
56/100
Position
OVERSOLD
30-Day Fair Range
$81.32 – $118.43
Position: OVERSOLD
Forward P/E & Valuation
14.7x
CHEAP
vs 35.6x historical avg
Wall Street Target
$142.60
+94.4% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$70.51 / $88.59
Trend: Sideways
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$242.61
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$150.64
51.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $73.35, which is considered oversold relative to its 30-day fair value range of $81.32 to $118.43. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.7) compared to its historical average (35.6). Remarkably, the market is currently pricing in an annual earnings decline of 25.5% over the next few years. This pessimistic expectation contrasts with the company's recent 531.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CORT is showing sideways momentum. Immediate support is located at $70.51, while resistance sits at $88.59.
Market Sentiment: CORT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $142.60 (+94.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CORT is showing sideways momentum. Immediate support is located at $70.51, while resistance sits at $88.59.
Market Sentiment: CORT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $142.60 (+94.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$81.32 -
$118.43
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Trading Range & Key Levels
30-Day Trading Range
$81.32 -
$118.43
Current vs Trading Range
OVERSOLD
Support Level
$70.51
Resistance Level
$88.59
Current Trend
Sideways
Technical data as of
Nov 10, 2026
Protect Your Profits
Holding CORT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 94.4% below Wall St target ($142.60)
- CAUTION: Bottoming setup, but lagging the sector by 20% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-10.5%) - monitor closely
Fundamental Context
Forward P/E (Next Year Est.)
14.72
Wall Street Target
$142.60
(+94.4%)
Revenue Growth (YoY)
64.0%
Earnings Growth (YoY)
531.3%
Profit Margin
16.8%
Valuation Discount vs History
-25.5% cheaper
PE vs Historical
14.7 vs 35.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-25.5%
(market-implied from PE analysis)
1-Year Target
$66.02
(-10%)
2-Year Target
$59.41
(-19%)
3-Year Target
$53.47
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→36)
$129.33
(+76%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 117.0%)
$334.02
(+355%)
Base:
(SPY PE: 14.7, Growth: 117.0%)
$247.56
(+238%)
Bear:
(PE: 12.5, Growth: 117.0%)
$210.42
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Forward PE: 14.79 | Forward EPS (Implied): $4.96
Bull Case
$88.57
(+21%)
Analyst growth 15.0%, PE expands to 15.5
Base Case
$73.35
(0%)
Market implied 0.0%, PE stable at 14.8
Bear Case
$56.11
(-24%)
Severe decline -15.0%, PE contracts to 13.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.7 to 35.6
Stabilization Target:
$177.41
(+141.9%)
PE Expansion Potential:
+141.9%
Share CORT Analysis
Share this live CORT analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (CORT)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 8, 2026
Daily AI digest
AI Retail Discussion Summary:
A bullish trader on StockTwits calculates a potential valuation of $4.05 billion for Cortexyme ($CORT) based on the conservative assumption of peak annual sales of $0.9 billion for Korlym in 2026.
Key Retail Themes:
Valuation
Peak Annual Sales
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 10, 2026 10:36 PM ET
Data refreshes hourly during market hours. Next update: 11:36 PM
Data refreshes hourly during market hours. Next update: 11:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 43 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 37 SELL |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 39 SELL |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$155 | 45 HOLD |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CORT Research Pages
